Sunil Agarwal - Juno Therapeutics President of Research & Development
President
Dr. Sunil Agarwal is President of Research Development of the Company. Prior to joining us, Dr. Agarwal was a private equity partner at Sofinnova Ventures, a VC firm that focuses largely on life science investments, beginning in August 2016. From July 2014 to August 2016, he was executive vice president and chief medical officer at Ultragenyx Pharmaceutical Inc., clinicalstage biopharmaceutical company focused on the development of products for rare and ultrarare disease, with a focus on serious, debilitating genetic diseases. From September 2003 to July 2014, Dr. Agarwal worked at Genentech Inc. in various positions of increasing responsibility, most recently as senior vice president, global development head for ophthalmology, metabolism, neuroscience, immunology, and infectious diseases. Dr. Agarwal serves on the board of directors of Calithera Biosciences, Inc. and MyoKardia Inc. Dr. Agarwal received a B.S. in Neurobiology from Cornell University in 1992 and an M.D. from Tufts University School of Medicine in 1996. Dr. Agarwal was a pediatric resident at Children National Medical Center from 1996 to 1999. since 2017.
| Age | 46 |
| Tenure | 7 years |
| Phone | 206 582-1600 |
| Web | www.junotherapeutics.com |
Juno Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1707) % which means that it has lost $0.1707 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2149) %, meaning that it created substantial loss on money invested by shareholders. Juno Therapeutics' management efficiency ratios could be used to measure how well Juno Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 10.01 M in liabilities with Debt to Equity (D/E) ratio of 0.8, which is about average as compared to similar companies. Juno Therapeutics has a current ratio of 4.67, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Juno Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Juno Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Juno Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Juno to invest in growth at high rates of return. When we think about Juno Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Michael Werdann | NETGEAR | 56 | |
| Leslie Kratcoski | GMS Inc | N/A | |
| Greg Henderson | Analog Devices | 49 | |
| Frank Pacholec | Stepan Company | 62 | |
| Necip Sayiner | Renesas Electronics | 52 | |
| Scott Deakin | GMS Inc | 58 | |
| Michael Hannawald | Renesas Electronics | N/A | |
| Craig Brosious | Bel Fuse A | 61 | |
| William Matson | Analog Devices | 54 | |
| Courteny Ryan | Jabil Circuit | 47 | |
| Scott Behrens | Stepan Company | 54 | |
| Thomas Wessel | Analog Devices | 47 | |
| Arthur Mergner | Stepan Company | 60 | |
| Rick Hess | Analog Devices | 61 | |
| William Peters | Jabil Circuit | 53 | |
| Tamesa Rogers | NETGEAR | 50 | |
| Yusuf Jamal | Analog Devices | 40 | |
| Gerd Look | Renesas Electronics | N/A | |
| Steven Pietkiewicz | Analog Devices | 58 | |
| Tetsuya Tsurumaru | Renesas Electronics | 63 | |
| Martin Cotter | Analog Devices | 59 | |
Management Performance
| Return On Equity | -0.21 | |||
| Return On Asset | -0.17 |
Juno Therapeutics Leadership Team
Elected by the shareholders, the Juno Therapeutics' board of directors comprises two types of representatives: Juno Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Juno. The board's role is to monitor Juno Therapeutics' management team and ensure that shareholders' interests are well served. Juno Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Juno Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Howard Pien, Chairman of the Board | ||
| Hal Barron, Director | ||
| Sunil Agarwal, President of Research & Development | ||
| Richard Klausner, Director | ||
| Mark Frohlich, Executive Vice President - Research and Development | ||
| Mary Wilderotter, Independent Director | ||
| Hans Bishop, Co-Founder, CEO and President and Director | ||
| Hyam Levitsky, Executive vice president - Research, chief scientific officer | ||
| Robert Azelby, Executive Vice President Chief Commercial Officer | ||
| Ann Lee, Executive Vice President - Technical Operations | ||
| Patrick Yang, Executive Vice President | ||
| Robert Nelsen, Co-Founder, Director, Member of Compensation Committee and Member of Nominating and Governance Committee | ||
| Thomas Daniel, Director | ||
| Jay Flatley, Director | ||
| Anthony Evnin, Independent Director | ||
| Cynthia Elkins, CIO | ||
| Rupert Vessey, Director | ||
| Steven Harr, CFO, Head of Corporate Development | ||
| Bernard Cassidy, General Counsel, Secretary | ||
| Marc TessierLavigne, Independent Director |
Juno Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Juno Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | |||
| Return On Asset | -0.17 | |||
| Operating Margin | (342.91) % | |||
| Current Valuation | 8.92 B | |||
| Shares Outstanding | 116.11 M | |||
| Shares Owned By Insiders | 13.58 % | |||
| Shares Owned By Institutions | 80.59 % | |||
| Number Of Shares Shorted | 8.19 M | |||
| Price To Earning | (15.21) X | |||
| Price To Book | 8.60 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Juno Stock
If you are still planning to invest in Juno Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Juno Therapeutics' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stocks Directory Find actively traded stocks across global markets |